Genetic immunization with CDR3-based fusion vaccine confers protection and long-term tumor-free survival in a mouse model of lymphoma.
Therapeutic vaccination against idiotype is a promising strategy for immunotherapy of B-cell malignancies. We have previously shown that CDR3-based DNA immunization can induce immune response against lymphoma and explored this strategy to provide protection in a murine B-cell lymphoma model. Here we performed vaccination employing as immunogen a naked DNA fusion product. The DNA vaccine was generated following fusion of a sequence derived from tetanus toxin fragment C to the V(H)CDR3(109-116) epitope. Induction of tumor-specific immunity as well as ability to inhibit growth of the aggressive 38C13 lymphoma and to prolong survival of vaccinated mice has been tested. We determined that DNA fusion vaccine induced immune response, elicited a strong protective antitumor immunity, and ensured almost complete long-term tumor-free survival of vaccinated mice. Our results show that CDR3-based DNA fusion vaccines hold promise for vaccination against lymphoma.
Iurescia
Sandra
S
Institute of Neurobiology and Molecular Medicine, Department of Medicine, National Research Council (CNR), Via Fosso del Cavaliere 100, 00133 Rome, Italy.
Fioretti
Daniela
D
Pierimarchi
Pasquale
P
Signori
Emanuela
E
Zonfrillo
Manuela
M
Tonon
Giancarlo
G
Fazio
Vito M
VM
Rinaldi
Monica
M
D000818:Animals; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology / Q000378:metabolism; D016009:Chi-Square Distribution; D022801:Complementarity Determining Regions / Q000235:genetics / Q000276:immunology*; D018274:Electroporation; D005434:Flow Cytometry; D007371:Interferon-gamma / Q000378:metabolism; D053208:Kaplan-Meier Estimate; D016393:Lymphoma, B-Cell / Q000276:immunology / Q000517:prevention & control / Q000628:therapy*; D008297:Male; D051379:Mice; D008809:Mice, Inbred C3H; D010446:Peptide Fragments / Q000235:genetics / Q000276:immunology*; D013744:Tetanus Toxin / Q000235:genetics / Q000276:immunology*; D019444:Vaccines, DNA / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology*; D023041:Xenograft Model Antitumor Assays
D022801:Complementarity Determining Regions; D010446:Peptide Fragments; D013744:Tetanus Toxin; D019444:Vaccines, DNA; C040635:tetanus toxin fragment C; D007371:Interferon-gamma
Blood. 2002 Mar 1;99(5):1517-26
11861263
Blood. 1997 May 1;89(9):3129-35
9129015
Biochem Biophys Res Commun. 2008 May 30;370(2):279-84
18364239
Int Immunol. 2007 Nov;19(11):1291-301
17906339
J Immunol. 2007 Oct 1;179(7):4741-53
17878373
Adv Cancer Res. 2006;95:203-47
16860659
Nat Biotechnol. 1999 Mar;17(3):253-8
10096292
Nat Med. 1996 Jan;2(1):52-8
8564842
Nat Rev Genet. 2008 Oct;9(10):776-88
18781156
Cancer Detect Prev. 2001;25(5):470-8
11718453
CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29
14974761
Nat Med. 1996 Sep;2(9):1038-41
8782465
Clin Cancer Res. 2004 Dec 15;10(24):8309-17
15623607
Cancer Res. 2001 Feb 15;61(4):1555-62
11245465
J Immunol. 2001 Aug 1;167(3):1558-65
11466377
J Immunol. 1987 Oct 15;139(8):2825-33
3498771
Eur J Immunol. 1989 Dec;19(12):2237-42
2481588
Expert Rev Vaccines. 2006 Jun;5(3):381-94
16827622
Dev Comp Immunol. 2003 Jan;27(1):55-77
12477501
J Clin Invest. 2004 May;113(10):1498-510
15146248
Gene Ther. 2000 Apr;7(7):605-11
10819576
Nat Immunol. 2004 Nov;5(11):1143-8
15475958
Blood. 2003 Jun 15;101(12):4930-6
12576325
Trends Mol Med. 2001 Dec;7(12):566-72
11733220
Gene Ther. 2001 Aug;8(16):1264-70
11509960
DNA Cell Biol. 2004 Jun;23(6):395-402
15231073
Nat Rev Cancer. 2008 Feb;8(2):108-20
18219306
J Immunol. 1993 Sep 1;151(5):2871-6
8360497
J Steroid Biochem Mol Biol. 2008 Apr;109(3-5):230-2
18406604
Immunogenetics. 1999 Nov;50(3-4):213-9
10602881
Blood Rev. 2009 May;23(3):137-42
18951668
Eur J Immunol. 1993 Feb;23(2):425-32
7679644
Blood. 2009 Jan 1;113(1):37-45
18832136
Cancer Immunol Immunother. 2008 Nov;57(11):1635-45
18386000
J Immunol. 1997 Aug 15;159(4):1885-92
9257853
Nat Med. 1998 Nov;4(11):1281-6
9809552
Biochem Biophys Res Commun. 2009 Jul 10;384(4):405-8
19410556
Vaccine. 2001 Feb 28;19(15-16):1931-9
11228363
Nature. 2003 Feb 20;421(6925):852-6
12594515
Curr Opin Oncol. 2005 Sep;17(5):432-40
16093791
N Engl J Med. 1992 Oct 22;327(17):1209-15
1406793
J Immunol. 1996 Dec 15;157(12):5503-11
8955200
Immunol Rev. 2004 Jun;199:156-80
15233733
Cancer Gene Ther. 2003 May;10(5):365-76
12719706
Eur J Immunol. 1977 Aug;7(8):574-9
409606